ES2486845T3 - Torio-227 para ser usado en radioterapia de enfermedad de partes blandas - Google Patents

Torio-227 para ser usado en radioterapia de enfermedad de partes blandas Download PDF

Info

Publication number
ES2486845T3
ES2486845T3 ES04727587.0T ES04727587T ES2486845T3 ES 2486845 T3 ES2486845 T3 ES 2486845T3 ES 04727587 T ES04727587 T ES 04727587T ES 2486845 T3 ES2486845 T3 ES 2486845T3
Authority
ES
Spain
Prior art keywords
thorium
addressing
effective amount
tissue disease
soft tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04727587.0T
Other languages
English (en)
Inventor
Roy Larsen
Oyvind Bruland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AS
Original Assignee
Algeta ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0308731.9A external-priority patent/GB0308731D0/en
Application filed by Algeta ASA filed Critical Algeta ASA
Application granted granted Critical
Publication of ES2486845T3 publication Critical patent/ES2486845T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

Utilización de una cantidad terapéuticamente eficaz de un complejo de torio-227 y complejante que se dirige a las partes blandas, para la fabricación de un medicamento para el tratamiento de enfermedad de partes blandas en un sujeto mamífero, en donde dicha cantidad eficaz es tal que al usarla se genera in vivo una cantidad aceptablemente no mielotóxica de radio-223 por desintegración nuclear del torio-227 administrado, y en donde el torio-227 está conjugado a un complejante de direccionamiento, en donde el complejante comprende un resto de direccionamiento con bioafinidad, en donde dicho resto de direccionamiento es uno que sirve para dirigir el complejo a la parte blanda a tratar, excluidos los osteótropos, liposomas y anticuerpos o fragmentos de anticuerpo conjugados a folato, y en donde la cantidad terapéuticamente eficaz de torio-227 es de al menos 25 kBq/kg.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
E04727587
30-07-2014
Tabla 6
Parámetros
Toxicidad Dosis única / kBq/kg Retratamiento Varias dosis / kBq/kg
Grados CTC
46 93 163 213 250 5 x 50 2 x 125
n = 5
n = 5
n = 5
n = 5
n = 5
n = 2 n = 3 n = 3
Plaquetas
0 5 5 4 5 2 2 2 3
1
0 0 1 0 3 0 1 0
Neutrófilos
0 4 3 3 2 2 2 1 3
1
0 1 0 1 0 0 0 0
2
1 1 1 2 2 0 2 0
3
0 0 1 0 1 0 0 0
Glóbulos blancos
0 4 4 3 2 2 2 1 2
1
0 0 0 0 0 0 0 0
2
1 1 1 2 2 0 2 1
3
0 0 1 1 1 0 0 0
Hemoglobina
0 4 2 4 2 2 1 0 0
1
0 2 0 2 3 1 2
1
2
1 1 1 1 0 0 1
2
16

Claims (1)

  1. imagen1
    imagen2
ES04727587.0T 2003-04-15 2004-04-15 Torio-227 para ser usado en radioterapia de enfermedad de partes blandas Expired - Lifetime ES2486845T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0308731.9A GB0308731D0 (en) 2003-04-15 2003-04-15 Method of radiotherapy
GB0308731 2003-04-15
PCT/GB2004/001654 WO2004091668A1 (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease

Publications (1)

Publication Number Publication Date
ES2486845T3 true ES2486845T3 (es) 2014-08-19

Family

ID=35385222

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04727587.0T Expired - Lifetime ES2486845T3 (es) 2003-04-15 2004-04-15 Torio-227 para ser usado en radioterapia de enfermedad de partes blandas

Country Status (19)

Country Link
EP (1) EP1617876B1 (es)
JP (2) JP5006032B2 (es)
KR (2) KR20060015507A (es)
CN (1) CN100586484C (es)
AU (1) AU2004229218B2 (es)
BR (1) BRPI0409387B8 (es)
CA (1) CA2522148C (es)
CY (1) CY1115407T1 (es)
DK (1) DK1617876T3 (es)
EA (1) EA008195B1 (es)
ES (1) ES2486845T3 (es)
HK (1) HK1094150A1 (es)
IL (1) IL171148A (es)
MX (1) MXPA05010804A (es)
NO (1) NO332931B1 (es)
NZ (3) NZ543044A (es)
PL (1) PL1617876T3 (es)
PT (1) PT1617876E (es)
ZA (1) ZA200507983B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008195B1 (ru) * 2003-04-15 2007-04-27 Алгета Ас Применение тория-227 в лучевой терапии заболеваний мягких тканей
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
ES2952744T3 (es) 2016-12-15 2023-11-03 Nestle Sa Composiciones y procedimientos que modulan los glóbulos blancos o los neutrófilos en un animal de compañía
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053196T3 (es) * 1989-06-19 1994-07-16 Akzo Nv Metodo para la produccion de un radioinmunoconjugado.
EP0662842A1 (en) * 1992-04-13 1995-07-19 The Dow Chemical Company Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
CA2381123C (en) * 2000-02-25 2011-10-04 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
ITMI20022411A1 (it) * 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
EA008195B1 (ru) * 2003-04-15 2007-04-27 Алгета Ас Применение тория-227 в лучевой терапии заболеваний мягких тканей

Also Published As

Publication number Publication date
EP1617876A1 (en) 2006-01-25
IL171148A (en) 2013-12-31
NO20055390L (no) 2006-01-16
NZ543044A (en) 2010-04-30
KR20060015507A (ko) 2006-02-17
CN1805760A (zh) 2006-07-19
CY1115407T1 (el) 2017-01-04
BRPI0409387A (pt) 2006-04-18
CN100586484C (zh) 2010-02-03
JP5006032B2 (ja) 2012-08-22
MXPA05010804A (es) 2006-03-09
ZA200507983B (en) 2007-03-28
EP1617876B1 (en) 2014-05-14
NZ595758A (en) 2013-02-22
DK1617876T3 (da) 2014-07-21
JP5468597B2 (ja) 2014-04-09
BRPI0409387B8 (pt) 2021-05-25
CA2522148A1 (en) 2004-10-28
JP2006523664A (ja) 2006-10-19
KR101274867B1 (ko) 2013-06-13
AU2004229218A1 (en) 2004-10-28
NO20055390D0 (no) 2005-11-15
NO332931B1 (no) 2013-02-04
PL1617876T3 (pl) 2015-03-31
BRPI0409387B1 (pt) 2021-05-11
AU2004229218B2 (en) 2009-05-07
CA2522148C (en) 2010-07-13
KR20110022743A (ko) 2011-03-07
JP2012051942A (ja) 2012-03-15
PT1617876E (pt) 2014-08-04
EA008195B1 (ru) 2007-04-27
EA200501456A1 (ru) 2006-06-30
NZ606996A (en) 2014-08-29
HK1094150A1 (en) 2007-03-23

Similar Documents

Publication Publication Date Title
Wang et al. Effect of shock wave therapy on acute fractures of the tibia: a study in a dog model.
Ueno et al. A clinicopathologic study of ameloblastoma
Pasquier et al. Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review
Thoms Jr et al. Multimodal treatment for inflammatory breast cancer
Franzén et al. Oral implant rehabilitation of patients with oral malignancies treated with radiotherapy and surgery without adjunctive hyperbaric oxygen.
Brusamolino et al. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity
ES2486845T3 (es) Torio-227 para ser usado en radioterapia de enfermedad de partes blandas
RU2012106620A (ru) Комбинации и способы введения терапевтических средств и комбинированной терапии
Silverberg et al. Osteoclastoma‐like giant cell tumor of the thyroid. Report of a case with prolonged survival following partial excision and radiotherapy
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
Kennedy et al. Combination versus successive single agent chemotherapy in lymphocytic lymphoma
ATE454166T1 (de) Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
Mark et al. Fibrosarcoma of the head and neck: the UCLA experience
DE69232518T2 (de) Verwendung von Perfluorkohlenwasserstoffen zur Herstellung von Potenzierungsmitteln für die ultraschallvermittelte Hyperthermiebehandlung von biologischen Geweben
COLEMAN Chemotherapy for large-cell lymphoma: optimism and caution
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
BR0213906A (pt) Métodos para a produção de um efeito anti-angiogênico e ou redutor da permeabilidade vascular em um animal de sangue quente, e para o tratamento de um câncer em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6474 ou um seu sal farmaceuticamente aceitável e um taxano
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
Frankenthaler et al. Fibrosarcoma of the head and neck
Oh et al. Nongastric marginal zone B‐cell lymphoma: Analysis of 247 cases
FR2375867A1 (fr) Medicament a base de dehydro-oligopeptides destine a la resolution d'une tumeur ou d'un tissu
Alessi et al. Osteomyelitis of the clavicle
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
MAEDA et al. High-energy, low-dose radiation therapy for aneurysmal bone cyst: report of a case